Jazz Pharmaceuticals JAZZ Trading securities, cost
Trading securities, cost at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's trading securities, cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's trading securities, cost?
- Jazz Pharmaceuticals (JAZZ) reported trading securities, cost of $4.3M in Q1 2026.
- How has Jazz Pharmaceuticals's trading securities, cost changed year-over-year?
- Jazz Pharmaceuticals's trading securities, cost decreased by 0.0% year-over-year, from $4.3M to $4.3M.
- What is the long-term trend for Jazz Pharmaceuticals's trading securities, cost?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's trading securities, cost has grown at a -7.9% compound annual growth rate (CAGR), from $5.5M to $4.3M.